Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension (Q40576215)

21 September 2017

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension (English)

1 reference

21 September 2017

Horst Olschewski

4

0 references

Norbert Weissmann

Norbert Weissmann

7

0 references

Ralph T Schermuly

Ralph T Schermuly

3

0 references

Friedrich Grimminger

Friedrich Grimminger

11

0 references

Werner Seeger

Werner Seeger

10

0 references

Hossein A Ghofrani

1

Hossein A Ghofrani

1 reference

21 September 2017

9

Beate Enke

1 reference

21 September 2017

5

Ralph Wiedemann

1 reference

21 September 2017

6

André Kreckel

1 reference

21 September 2017

8

Stefanie Ghofrani

1 reference

21 September 2017

Frank Rose

2

1 reference

PubMed ID

12849677

21 September 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

Journal of the American College of Cardiology

21 September 2017

1 reference

21 September 2017

42

1 reference

21 September 2017

158-164

1 reference

21 September 2017

1

1 reference

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Aerosolised prostacyclin in adult respiratory distress syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Inhaled iloprost for severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Low-dose Systemic Phosphodiesterase Inhibitors Amplify the Pulmonary Vasodilatory Response to Inhaled Prostacyclin in Experimental Pulmonary Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Bosentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Medical therapy of pulmonary hypertension. Conventional therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

Lung transplantation for pulmonary vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900555-2

7 January 2021

10.1016/S0735-1097(03)00555-2

Identifiers

DOI

1 reference

21 September 2017

1 reference

PubMed ID

12849677